Top Markets
Coin of the day
RVL Pharmaceuticals plc RVL Pharmaceuticals plc

RVL Pharmaceuticals plc

OSMT
Peringkat dalam Saham #25637
Osmotica Pharmaceuticals plc, headquartered in Bridgewater, New Jersey,... Osmotica Pharmaceuticals plc, headquartered in Bridgewater, New Jersey, operates as a fully integrated biopharmaceutical company. The firm's primary focus involves the development and commercialization of various pharmaceutical products, serving markets in the United States, Argentina, and Hungary. Their actively promoted product lineup includes M-72, an extended-release methylphenidate hydrochloride tablet designed to treat attention deficit hyperactivity disorder (ADHD), and Osmolex ER, an extended-release amantadine formulation used for Parkinson's disease and specific drug-induced movement disorders in adults. They also offer Upneeq, an oxymetazoline hydrochloride ophthalmic solution prescribed for blepharoptosis (drooping eyelids). In their development pipeline, Arbaclofen extended-release tablets are currently undergoing Phase III clinical trials for managing spasticity associated with multiple sclerosis, while OS870 is in Phase I trials for neurodegenerative disorders. Beyond these, Osmotica provides women's health solutions, such as Divigel for menopause management and OB Complete, a dietary supplement tailored for the prenatal, pregnancy, and postnatal periods. The company's broader portfolio also encompasses numerous non-promoted pharmaceutical products. These include methylphenidate ER tablets for ADHD, venlafaxine ER tablets addressing major depressive and social anxiety disorders, hydromorphone ER for pain relief, and nifedipine ER for hypertension. Other offerings feature sodium benzoate/sodium phenylacetate for hyperammonemia, oxybutynin ER for overactive bladder, and prescription prenatal vitamins. Additionally, their non-promoted items comprise Lorzone, an immediate-release chlorzoxazone for acute musculoskeletal pain (when combined with rest and physical therapy), ConZip (tramadol hydrochloride) for pain management, and nitrofurantoin for urinary tract infections, alongside Osmodex and various other abbreviated new drug applications.
Harga Saham
$1.11
Terakhir disinkronkan: 2022-01-18
Kapitalisasi Pasar
$47.57M
Perubahan (1 hari)
-1.77%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan RVL Pharmaceuticals plc (OSMT)

Kategori

Jumlah saham beredar untuk RVL Pharmaceuticals plc (OSMT)
Jumlah saham beredar per August 2026: 0
Menurut laporan keuangan terbaru dan harga saham RVL Pharmaceuticals plc, jumlah saham beredar saat ini adalah 0. Pada akhir August 2026, perusahaan memiliki 0 saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk RVL Pharmaceuticals plc (OSMT) dari 2026 hingga 2026
Saham beredar pada akhir setiap tahun
Tahun Saham Beredar Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Saham beredar untuk perusahaan serupa atau pesaing
Perusahaan Saham Beredar Perbedaan Negara
253.90M -
US
62.19M -
NL
483.58M -
AU
- -
CH
396.00M -
US